High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia

Leukemia

Volumn 20, Issue 3, 2006, Pages 400-403

  Rea, D ^a   Legros, L ^b   Raffoux, E ^a   Thomas, X ^c   Turlure, P ^d   Maury, S ^e   Dupriez, B ^f   Pigneux, A ^g   Choufi, B ^h   Reman, O ⁱ   Stephane D ^j   Royer, B ^k   Vigier, M ^l   Ojeda Uribe, M ^m   Recher, C ⁿ   Dombret, H ^a   Huguet, F ⁿ   Rousselot, P ^a,o  

^a SAINT LOUIS HOSPITAL   (France)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f Service d'Hematologie Clinique   (France)

^g HAUT LÉVÊQUE HOSPITAL   (France)

^h CENTRE JEAN PERRIN   (France)

ⁱ CHU Clemenceau   (France)

^j LILLE UNIVERSITY HOSPITAL   (France)

^k AMIENS UNIVERSITY HOSPITAL   (France)

^l HÔTEL DIEU   (France)

^m Hôpitaux Universitaires de Strasbourg   (France)

ⁿ CHU PURPAN   (France)

^o CENTRE HOSPITALIER DE VERSAILLES   (France)

more..

Author keywords

Acute leukemia; Chemotherapy; Combination; Imatinib

Indexed keywords

BCR ABL PROTEIN; COTRIMOXAZOLE; DEXAMETHASONE; ETOPOSIDE; IMATINIB; VALACICLOVIR; VINCRISTINE; VINDESINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST CELL CRISIS; BLOOD TOXICITY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER DISEASE; LUNG FIBROSIS; LYMPHOBLAST; MALE; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

EID: 33644550315     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404115     Document Type: Article

References (16)

1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
2. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
3. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 2001; 293: 876-880.
4. Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-1862.
5. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphiachromosome-positive leukaemia to STI571: A prospective study. Lancet 2002; 359: 487-491.
6. Hochhaus A, La Rosee P. Imatinib therapy in chronic myelogenous leukemia: Strategies to avoid and overcome resistance. Leukemia 2004; 8: 1321-1331.
7. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873-2878.
8. Kantarjian HM, Talpaz M, O'Brien S, Giles F, Garcia-Manero G, Faderl S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 10: 473-475.
9. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
10. Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 97: 1999-2007.
11. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396-4407.
12. Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL positive acute lymphoblastic leukemia. Blood 2004; 104: 3507-3512.
13. Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19: 1509-1516.
14. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086.
15. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'eal-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2118-2357.
16. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: Correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128-2137.